These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30115553)

  • 1. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial.
    Sarris J; Byrne GJ; Bousman C; Stough C; Murphy J; MacDonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng C; Mischoulon D
    Eur Neuropsychopharmacol; 2018 Oct; 28(10):1126-1136. PubMed ID: 30115553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial.
    Sarris J; Murphy J; Stough C; Mischoulon D; Bousman C; MacDonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng CH; Byrne GJ
    Psychopharmacology (Berl); 2020 Jan; 237(1):209-218. PubMed ID: 31712971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial.
    Sarris J; Byrne GJ; Stough C; Bousman C; Mischoulon D; Murphy J; Macdonald P; Adams L; Nazareth S; Oliver G; Cribb L; Savage K; Menon R; Chamoli S; Berk M; Ng CH
    J Affect Disord; 2019 Feb; 245():1007-1015. PubMed ID: 30699842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
    Papakostas GI; Mischoulon D; Shyu I; Alpert JE; Fava M
    Am J Psychiatry; 2010 Aug; 167(8):942-8. PubMed ID: 20595412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response.
    Sarris J; Papakostas GI; Vitolo O; Fava M; Mischoulon D
    J Affect Disord; 2014 Aug; 164():76-81. PubMed ID: 24856557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder.
    Mischoulon D; Alpert JE; Arning E; Bottiglieri T; Fava M; Papakostas GI
    J Clin Psychiatry; 2012 Jun; 73(6):843-8. PubMed ID: 22687580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
    Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
    J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression.
    Toniolo RA; Silva M; Fernandes FBF; Amaral JAMS; Dias RDS; Lafer B
    J Neural Transm (Vienna); 2018 Feb; 125(2):247-257. PubMed ID: 29177955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P; Scapicchio P; Chiaie RD
    Int J Neuropsychopharmacol; 2002 Dec; 5(4):287-94. PubMed ID: 12466028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
    Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
    Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
    J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.
    Sanacora G; Johnson MR; Khan A; Atkinson SD; Riesenberg RR; Schronen JP; Burke MA; Zajecka JM; Barra L; Su HL; Posener JA; Bui KH; Quirk MC; Piser TM; Mathew SJ; Pathak S
    Neuropsychopharmacology; 2017 Mar; 42(4):844-853. PubMed ID: 27681442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.